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To obtain experimental evidence on the therapeutic eﬃcacy of essential oils in aromatherapy for inﬂammatory diseases, we ex-
amined the eﬀects of geranium oil on carrageenan-induced and collagen II-induced inﬂammation in mice, to assess acute and
chronic anti-inﬂammatory activities of the oil. Single intraperitoneal injection of 5μL of geranium oil clearly suppressed the
carrageenan-induced footpaw edema and increase in tissue myeloperoxidase activity, and repeated administration of the oil sup-
pressed collagen-induced arthritis. These results revealed that geranium oil suppressed both acute and chronic inﬂammatory
responses in mice
Copyright © 2006 Naho Maruyama et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
INTRODUCTION
Aromatherapy is one of the alternative medicines using es-
sentialoilsandhaslongbeenusedasanherbalmedicine.Re-
centlyessentialoilshavebeenempiricallyusedworldwidefor
clinical conditions including various kinds of inﬂammatory
diseases, such as allergy,rheumatism, and arthritis. These ac-
tivities have mainly been recognized through clinical experi-
ence, but there has been relatively little evidence about the
pharmacological actions of these oils.
Several investigators have suggested that tea tree [1, 2]
and lavender [3] oils suppressed allergic symptoms through
the suppression of histamine release [4, 5] and cytokine pro-
duction [6] in vitro and in vivo. Several essential oils such as
eucalyptus [7] and lavender [8] oils inhibited carrageenan-
induced paw edema. Moreover, in human, skin application
of tea tree oil was reported to suppress the edema induced by
intradermal injection of histamine [9]. However, the chronic
eﬀects of essential oils using inﬂammatory mice model have
hardly been investigated.
Previouslywereportedthattheessentialoilssuchasgera-
nium oil suppressed the adherence response of neutrophils
in vitro [10], and that the intraperitoneal administration of
geranium oil lowered neutrophil recruitment into the peri-
toneal cavity induced by injection of a chemotactic agent,
casein in vivo [11]. We also reported that both intraperi-
toneal and cutaneous applications of the oil suppressed cel-
lular inﬂammation and neutrophil accumulation to the in-
ﬂammatory sites which were induced by curdlan, a linear
(1 → 3)-β-D-glucan known as an immunostimulating sub-
stance in fungi [12]. These results suggested the possibil-
ity that geranium oil might eﬀectively suppress symptoms
in inﬂammatory disease associated with neutrophil activi-
ties.
In the present study, we investigated the eﬀects of gera-
nium oil on carrageenan-induced foot edema and collagen-
induced arthritis, which are models for acute and chronic in-
ﬂammation accompanied by neutrophil accumulation.
MATERIALS AND METHODS
Essentialoils
Geranium oil was provided by Pranarom (Kenso-igakusha
Ltd, Tokyo, Japan). The oil was diluted to 0.625, 1.25,
2.5% solution by 2.5% dimethyl sulfoxide (DMSO), and
25μL of Tween 20 was added to 2mL of the essen-
tial oil solution. Main constituents of the oil based on
the company’s data were citronellol (22.42%), geraniol
(18.25%), linalool (5.59%), citronellyl formate (10.24%),
geranyl formate (7.36%), guaiadiene (6.88%), and isomen-
thone (7.58%).2 Mediators of Inﬂammation
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Figure 1: Eﬀects of intraperitoneal administration of geranium oil
onfootswellinginducedbycarrageenaninjection.Carrageenanwas
injected to left footpad of mice, and 10 minutes after the injection,
geranium oil or DMSO was given intraperitoneaouly. Six and 24
hours later, the increase of the foot thickness was measured. Each
value represents an average from 5 mice and the standard error.
∗P<. 05 diﬀerence from control.
Agents
Polyoxyethylene (20) sorbitan monolaurate (Tween 20) was
purchased from Wako Pure Chemical Industries, Ltd (Os-
aka, Japan). Bovine collagen II was from Cosmo Bio (Tokyo,
Japan), complete Freund’s adjuvant (CFA) was from DIFCO
(Michigan, USA). Carrageenan λ,H e x a d e c y l t r i m e t h y l a m -
moniumbromide(HTAB),humanmyeloperoxidase(MPO),
and tetramethylbenzidine (TMB) were purchased from
Sigma-Aldrich (Tokyo, Japan).
Animals
All animal experiments were performed according to the
guidelines for the care and use of animals approved by
Teikyo University. Six-week-old male DBA mice (Charles
River Japan, Inc, Kanagawa, Japan) were used for all animal
experiments. The photoperiods were adjusted to 12 hours of
light and 12 hours of darkness daily, and the environmental
temperature was constantly maintained at 21◦C. The mice
were kept in cages housing 4–6 animals and were given ad
libitum access to food and water.
Carrageenan-inducededema:footpadreaction
Footpad reaction was based on the method of Abe et al [13]
and partly modiﬁed. Ten mg of carrageenan were dissolved
in 1mL of saline and 0.05mL of the solution was injected to
the mouse left footpad to induce edema. The photos of feet
fromalateralviewweretakenbeforeand6and24hoursafter
carrageenan injection using a digital camera, and foot thick-
ness was measured from the photo (Figure 1). The edema
was calculated by the diﬀerence of thickness between 0 and
6o r2 4h o u r s .T e nm i n u t e sa f t e rc a r r a g e e n a ni n j e c t i o n ,t h e
mice were intraperitoneally given 0.2mL of 2.5% geranium
solution. A dose of 2.5% solution corresponds to 5μLo f
pure oil. Control mice received 0.2mL of 2.5% DMSO so-
lution. Mice were sacriﬁced by carbon dioxide 24 hours af-
ter carrageenan injection. The feet were resected 5mm above
their heels, soaked in 2mL of 80mM sodium phosphate
buﬀer, pH 5.4, containing 0.5% HTAB (0.5% HTAB solu-
tion), weighed and kept at −20◦C until the MPO assay. We
used a nontreated right foot of the same mice as a refer-
ence.
Myeloperoxidase(MPO)assay
The MPO assay was based on the method of De Young et al
[14] and partly modiﬁed. Frozen samples were thawed at
room temperature and homogenized at 0◦C using a Polytron
(Kinematica AG, Lucerne, Switzerland). The homogenates
were poured into sampling tubes and centrifuged at 12000×
ga t4 ◦Cf o r1 5m i n u t e s .
Triplicate 30μL samples of resulting supernatant were
poured into 96 well microtiter plates. For assay, 200μLo fa
mixture containing 100μL phosphate buﬀered saline, 85μL
of 0.22M sodium phosphate buﬀer, pH 5.4, and 15μLo f
0.017% hydrogen peroxide were added to the wells. The
reaction was started by the addition of 20μL of 18.4mM
TMB·2HCl in 8% aqueous dimethylformamide. Plates were
stirred and incubated at 37◦C for 3 minutes and then placed
on ice where the reaction in each well was stopped by addi-
tion of 30μL of 1.46M sodium acetate buﬀer, pH 3.0. The
MPO value was calculated by measuring the absorbance of
samplesat620nm(ODvalue)followedbyitsconversioninto
MPO values per foot.
Collagen-inducedarthritis
Induction of type II collagen-induced arthritis was based on
the method of Ochi et al [15] and partly modiﬁed.
Collagen II from bovine articular cartilage was dissolved
overnight at 4◦Ci n0 . 1Ma c e t i ca c i da tac o n c e n t r a t i o no f
2.5mg/mL. The solution was emulsiﬁed with 1.2 times vol-
ume of CFA, and 100μL of the emulsion were administered
subcutaneously at the base of the tail of the mice for immu-
nizationonday −21.Boosterinjectionof100μLoftheemul-
sion was given on day 0. Mice were intraperitoneally given
0.2mL of geranium oil solutions from day 0 to 21, 5 days per
week (injection period). Control mice were given 0.2mL of
2.5% DMSOsolution. Their weightand pawsweremeasured
2d a y se a c hw e e kf r o md a y0t o3 9 .
Mouse paws were scored for arthritis based on the
method of Kim et al [16] using a macroscopic scoring system
ranging from 0 to 4 (0, no swelling; 1, swelling of one joint;
2, two joints involved; 3, more than two joints involved; 4,
severe arthritis over the entire paw and joints). The arthritic
score for each mouse was the sum of the scores of all four
paws.Naho Maruyama et al 3
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Figure 2: Typical swelling of control mice and that of geranium-treated mice. Nontreated foot (a), carrageenan injected control (b), and
geranium-treated (c) feet 24 hours after carrageenan injection were shown. The mouse was administered with geranium oil 10 minutes after
carrageenan injection.
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Figure 3: Eﬀects of intraperitoneal administration of geranium oil
on foot swelling estimated by their weight. Carrageenan was in-
jected to left footpad of mice, and 10 minutes after the injection,
geranium oil or DMSO was given intraperitoneaouly. Twenty four
hours later, their feet were resected to measure their weight. Each
value represents an average from 5 mice and the standard error. ∗∗
P<. 01 diﬀerence from control.
Statisticalanalysis
Theresultswereexpressedbythemean ±standarderror.The
datawerestatisticallycomparedusingtheStudent’st-testand
the χ-square test.
RESULTS
Effectsofgeraniumoiloncarrageenan-induced
edemainthehindpawsofmice
Carrageenan injection to the footpad increased the foot
thickness of control mice by 1.68 ± 0.08mm after 6 hours
and the swelling continued for 24 hours (1.55 ± 0.16mm)
(Figure 1). Intraperitoneal injection of geranium oil signiﬁ-
cantly suppressed the increase in foot thickness both 6 and
24 hours after carageenan injection (0.96 ± 0.13mm and
0.91 ± 0.19mm, resp). Figure 2 shows photos of the typical
swelling of control mice and that of geranium-treated mice
24 hours after carageenan injection. These photos clearly
indicated that the foot treated with geranium oil was less
swollen than the control foot.
In order to conﬁrm the inﬂammatory response, foot
weights and MPO activity in foot homogenates were mea-
sured.
The weight of the carrageenan-injected control foot was
signiﬁcantly increased compared with the nontreated foot
(0.28 ± 0.01g and 0.17 ± 0.00g, resp), as shown in Figure 3.
This ﬁgure also shows that intraperitoneal injection of gera-
nium oil signiﬁcantly lowered the weight gain (0.21±0.01g).
The same feet were used for measurement of MPO ac-
tivity which represented the number of neutrophils. Car-
rageenan injection to the footpad induced a marked increase
of the MPO value of the foot compared with the nontreated
foot(61.51±16.84units/footand4.02±1.96units/foot,resp)
(Figure 4). Geranium oils suppressed the increase of MPO
value signiﬁcantly (44.38 ± 6.30units/foot). This suggested
that intraperitoneal injection of geranium oil lowered neu-
trophil accumulation to the carrageenan-injected foot.
Effectsofgeraniumoiloncollagen-induced
arthritisinmice
Next, we examined the eﬀects of the oil against the collagen-
induced arthritis in mice as a chronic inﬂammation model.
OneofcontrolmiceimmunizedwithcollagenII(ondays
−21 and 0) developed an edema (arthritis) from day 7, and
then most of them elicited edema, 6 of 10 on day 21 and 7
of 10 on day 39 (Figure 5). Their symptoms were aggravated
gradually after the second collagen II injection. In mice given
5μL of geranium oil, edema of the feet was observed only on
one animal with slight swelling. There were statistical diﬀer-
ences between control and the 5μLg e r a n i u mo i lg r o u p ,o n
day10andafterday17usingχ-squaretest.Noaggravationof
symptoms was observed even after completion of geranium
oil injection.4 Mediators of Inﬂammation
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Figure 4: Eﬀects of intraperitoneal administration of geranium oil
on MPO activity in foot homogenates. Carrageenan was injected to
left footpad of mice, and 10 minutes after the injection, geranium
oil or DMSO was given intraperitoneaouly. Twenty four hours later,
their feet were resected to measure their MPO activities. Each value
represents an average from 5 mice and the standard error. ∗P<. 05,
∗∗P<. 01 diﬀerence from control.
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Figure 5: Eﬀects of intraperitoneal administration of geranium oil
on the ratio of the mice which revealed feet swelling by collagen II
induction. Collagen II with CFA was subcutaneously injected to the
base of the tail of the mice on days −21 and 0. Geranium oils were
given from day 0 to 21, 5days/week. Each value represents percent-
ages of mice with foot swelling. ∗P<. 05 diﬀerence from control
using χ-square test.
Oral administration of indomethacin used as a reference
suppressedtheedemaduringtheinjectionperiod,but1week
after completion of injections the feet appeared to be swollen
(data not shown).
Time course of the score of inﬂammatory symptoms is
depicted in Figure 6. The symptoms of the control mice were
exacerbatedtime-dependently.Thescoreofthemiceinjected
with 5μL of geranium oil was clearly lower than that of con-
trol mice with statistical signiﬁcance on days 24, 35, and 39.
On the other hand, 1.25 and 2.5μL oils seemingly lowered
the scores, but the diﬀerences were not statistically signiﬁ-
cant.
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Figure 6: Eﬀects of intraperitoneal administration of geranium
oil on the inﬂammatory score. Collagen II with CFA was subcuta-
neouslyinjectedtothebaseofthetailofthemiceondays −21and0.
Geranium oils were given from day 0 to 21, 5days/week. The arthri-
tiswasscoredasdescribedinmaterialandmethods.Eachvaluerep-
resents an average from 5–10 mice and the standard error. ∗P<. 05
diﬀerence from control.
Figure 7showstypicalpicturesofthefeetofacontroland
a5μL geranium injected mouse.
Figure 8 indicates the change of body weight during
treatment. The weight of mice treated with geranium oil de-
creased immediately after oil injection. The reduction was
largest in the group injected with 5μL of geranium oil. Their
weight loss was gradually recovered, but the recovery was
slow in the groups injected with 2.5 and 5μLo fg e r a n i u m
oil. In the group injected with 5μL of the oil, 2 mice died on
days 18 and 21.
DISCUSSION
In the present study, we showed that intraperitoneal admin-
istration of geranium oil suppressed two types of inﬂamma-
tory responses, carrageenan-induced edema and collagen-
induced arthritis.
When mice received intraperitoneal injection of 5μL
of geranium oil 10 minutes after carrageenan injection,
carrageenan-induced edema was signiﬁcantly suppressed at
6 and 24 hours. This indicates that the suppressive eﬀect of
the oil on the acute inﬂammation continued at least for 24
hours. We also measured the weight and MPO activity as pa-
rameters of neutrophil accumulation at 24 hours, and the re-
sults suggest that the oil suppressed the acute inﬂammation
accompanied by neutrophil accumulation (Figures 3 and 4).
We previously reported that intraperitoneal administra-
tion of geranium oil suppressed the casein-induced accumu-
lation of neutrophils in the peritoneal cavity [11], and both
intraperitoneal and cutaneous applications of the oil sup-
pressed cellular inﬂammation and neutrophil accumulationNaho Maruyama et al 5
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Figure 7: Macroscopic arthritis of control mice and that of geranium-treated mice. The mice were treated as represented in the legend to
Figure 5 and their feet were observed on day 39. Arrows indicate the swelling of foot. (a) Control mouse; (b) mouse administered with 5μL
geranium oil.
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Figure 8: Changes in body weight during and after geranium oil
injectiontomice.CollagenIIwithCFAwassubcutaneouslyinjected
to the base of the tail of the mice on days −21 and 0. Geranium oils
were injected from day 0 to 21, 5days/week. Each value represents
anaverageof5–10miceandthestandarderror.  : death of mouse.
to the inﬂammatory sites which were induced by a (1 → 3)-
β-D-glucan, curdlan [12]. In this study, geranium oil inhib-
ited the carrageenan-induced edema from 6 hours and neu-
trophil accumulation for 24 hours. These indicate that gera-
nium oil suppresses the neutrophil accumulation in various
inﬂammatory responses from an early stage.
The cellular mechanism of the suppression of edema by
geranium oil remains to be clariﬁed. It is reported that car-
rageenan injection induced the production of histamine and
cytokine such as TNF-α [17, 18]. TNF-α is one of the ma-
jor inﬂammatory cytokines with the capacity to prime ac-
tivation of the neutrophils for their various functions [19].
In our previous study, we showed that geranium oil inhib-
ited TNF-α-induced neutrophil adherence to a plastic plate
at very low concentrations (0.00625%) in vitro [10], so we
can assume that this suppression might be partially caused
by inhibiting neutrophil response to TNF-α in vivo.
We also evaluated the long-term eﬀect of the oil us-
ing collagen-induced arthritis mouse as the chronic anti-
inﬂammatory disorder model. Collagen-induced arthritis
in mice has many characteristics in common with human
rheumatoid arthritis such as foot swelling and has been the
most used animal model for the disease [15, 20]. Five μLo f
geranium oil suppressed the swelling and the eﬀect contin-
ued even after cessation of oil injection. As far as we know,
thisistheﬁrstreportindicatingthatgeraniumoilsuppressed
thelaterphaseofinﬂammatoryresponseaswellastheearlier
phase in in vivo experiments.
Rheumatoid arthritis is considered an autoimmune dis-
ease involving joint inﬂammation associated with TNF-α
production. Various cells such as Th1 cells, neutrophils and
macrophages, and their cytokines such as IL1 and TNF in-
ﬁltrate the synovial tissues to destroy joints [21]. In our ex-
periments, geranium oil was administered to the mice after a
boosterinjectionofcollagenII.Wecanthereforeassumethat
the oil suppresses the later phase of autoimmune reaction, or
the onset of symptoms after autoimmune reaction, not the
early stage of the reaction.
Previous pathological studies [20, 22] on experimental
murine arthritis showed that there were marked edema of
synovium and inﬁltration of many polymorphonuclear cells
such as neutrophils in the early phase of arthritis onset, fol-
lowed by the chronic destructive phase in which pronounced
proliferation of synovium containing mononuclear cells was
observed. From these ﬁndings and our previous data, we can
speculate that geranium oil may suppress the onset of the
symptoms at least partially through inhibition of neutrophil6 Mediators of Inﬂammation
inﬁltration. To check this possibility, we wish to evaluate the
MPO value in further study.
Itwasnotedthat5μLofgeraniumoilsuppressedthefoot
swelling during and after the oil injection period, suggesting
along-lastingeﬀectofthisoil.Preliminarystudyshowedthat
indomethacin inhibited the swelling only during its admin-
istration, and 1 week after completion of the injection the
feet gradually swelled (data not shown). This indicates that
repetitive administration of the oil may elicit a long-lasting
eﬀect.
In aromatherapy, several essential oils can be applied as a
help in therapeutic treatments for inﬂammatory symptoms
withlesionalneutrophilaccumulation,suchasarthritis,aph-
thous stomatitis, lesional bacterial or fungal infections. Their
eﬀectiveness is postulated clinically, but little experimental
evidence has been obtained. Our two results give basic evi-
dence about the activity of geranium oil for both acute and
chronic inﬂammatory disorders.
In relation to the application of the essential oil, we must
mention its toxicity. In our later experiment, 2 mice of the
group which were intraperitoneally given 5μLo fg e r a n i u m
oil died during the experiment. The body weight of this
group was greatly reduced, so the administration protocol
might have been too severe for them. In order to develop a
less toxic administration procedure, it is our opinion that the
selection of administration routes of the essential oil must
be critical, since cutaneous application of geranium oil sup-
pressed the curdlan-induced skin inﬂammation without ap-
parent toxic response [12]. By optimizing the dosage and ad-
ministration route, we hope to propose safer and more eﬀec-
tive treatment protocol using essential oil for inﬂammatory
diseases.
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